Completed PHASE3 NCT01218308

A Study to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine in Children

Efficacy Study of GSK Biologicals' Quadrivalent Influenza Vaccine, GSK2282512A, (FLU Q-QIV) When Administered in Children

Sponsor: GlaxoSmithKline

Conditions Influenza

Interventions FluLaval® Quadrivalent Havrix™

Updated 8 times since 2017 Last updated: Jul 4, 2018 Started: Dec 9, 2010 Primary completion: Jan 9, 2012 Completion: Jan 9, 2012

Listed as NCT01218308, this PHASE3 trial focuses on Influenza and remains completed. Sponsored by GlaxoSmithKline, it has been updated 8 times since 2010, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Aug 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 3 earlier versions

Jun 2018 — Aug 2018 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Dec 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline

Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Adana, Turkey (Türkiye) , Ankara, Turkey (Türkiye) , Bangkok, Thailand , Beirut, Lebanon , City of Muntinlupa, Philippines , Dasmariñas, Cavite, Philippines , Dhaka, Bangladesh , Eskişehir, Turkey (Türkiye) , Izmir, Turkey (Türkiye) , Panama City, Panama and 2 more locations